ROS1
ROS1 gene fusions drive oncogenic signaling in lung and other cancers. These alterations predict response to ROS1-targeted therapies.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where ROS1 is defined directly in the indication labeling.
Approvals defined at the solid tumor level where ROS1 is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report ROS1 as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports ROS1 as part of its biomarker panel.
Reports ROS1 as part of its biomarker panel.
Reports ROS1 as part of its biomarker panel.